Abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to Lowell L. Hart, MD.
Original Article: Hart Recaps Data With Abemaciclib in HR+/HER2- Breast Cancer